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INTRODUCTION 
Chronic Obstructive Pulmonary Disease (COPD) is a major cause of 
chronic morbidity and mortality throughout the world. It is defined as 
preventable and treatable disease with some significant extra pulmonary 
effects that may contribute to the severity in individual patients1. Its 
pulmonary component is characterized by airflow limitation that is not fully 
reversible. The airflow limitation is usually progressive and associated with 
an abnormal inflammatory response of the lung to noxious particles or 
gases1. 
The impact of COPD on an individual patient depends on the severity 
of symptoms (especially breathlessness and decreased exercise capacity), 
systemic effects, and any co morbidities the patient may have—not just on 
the degree of airflow limitation. 
There is growing evidence for systemic inflammation in COPD. 
Increased circulating levels of inflammatory cytokines and acute phase 
proteins occur in stable disease, and COPD exacerbations are notably 
associated with pulmonary and systemic inflammation2. 
  
COPD is an important risk factor for atherosclerosis3-5. Even modest 
reductions in expiratory flow volumes elevate the risk of ischemic heart 
diseases, strokes, and sudden cardiac deaths 2- to 3-fold, independent of 
other risk factors3-7. Indeed, poor lung function has been shown to be a better 
predictor of all-cause and cardiac-specific mortality than established risk 
factors such as serum cholesterol5. Cardiovascular conditions are the leading 
cause of mortality among those with impaired lung function3, 5, 7. The 
mechanism or mechanisms responsible for this association, however, remain 
largely unknown 
Although the pathogenesis of atherothrombosis is complex and 
multifactorial, persistent low-grade systemic inflammation is believed to be 
one of the centerpieces in effecting clot formation8. 
The association of COPD with systemic inflammation and cardiac 
injury are analyzed in our study population. 
 
  
 
OBJECTIVES OF THE STUDY 
1.  To determine whether COPD is associated with increased circulating 
levels of CRP and other inflammatory markers. 
2.  To determine whether the intensity of the systemic inflammation is 
associated with the severity of airflow obstruction. 
3.  To find out whether systemic inflammation and COPD are associated 
with cardiac injury. 
 
 
 
 
 
 
 
  
REVIEW OF LITERATURE 
Chronic Obstructive Pulmonary Disease (COPD) is a major cause of 
chronic morbidity and mortality throughout the world. Many people suffer 
from this disease for years and die prematurely from it or its complications. 
COPD is the fourth leading cause of death in the world9, and further 
increases in its prevalence and mortality can be predicted in the coming 
decades10. 
Definition: According to Global initiative for chronic obstructive lung 
disease (GOLD1), COPD is a preventable and treatable disease with some 
significant extra pulmonary effects that may contribute to the severity in 
individual patients. Its pulmonary component is characterized by airflow 
limitation that is not fully reversible. The airflow limitation is usually 
progressive and associated with an abnormal inflammatory response of the 
lung to noxious particles or gases1. The term “emphysema” and “chronic 
bronchitis,” are not included in this definition. Emphysema, or destruction of 
the gas exchanging surfaces of the lung (alveoli), is a pathological term that 
is often (but incorrectly) used clinically and describes only one of several 
structural abnormalities present in patients with COPD1. Chronic bronchitis, 
or the presence of cough and sputum production for at least 3 months in each 
  
of two consecutive years, remains a clinically and epidemiologically useful 
term1. 
Worldwide, cigarette smoking is the most commonly encountered risk 
factor for COPD, although in many countries, air pollution resulting from 
the burning of wood and other biomass fuels has also been identified as a 
COPD risk factor1. 
The chronic airflow limitation characteristic of COPD is caused by a 
mixture of small airway disease (obstructive bronchiolitis) and parenchymal 
destruction (emphysema), the relative contributions of which vary from 
person to person1. 
Mechanisms Underlying Airflow Limitation in COPD 
 
                                           INFLAMMATION 
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SPIROMETRIC CLASSIFICATION OF SEVERITY 
 
Spirometry is essential for diagnosis and provides a useful description of the 
severity of pathological changes in COPD. Spirometry should be performed 
after the administration of an adequate dose of an inhaled bronchodilator 
(e.g., 400 mcg salbutamol) in order to minimize variability11. 
                              Spirometric Classification of COPD 
                      Severity Based on Post-Bronchodilator FEV11 
 
                Stage I: Mild                          FEV1/FVC < 0.70 
                                                           FEV1 ≥80% predicted 
 
           Stage II: Moderate                  FEV1/FVC < 0.70 
                                                           50% ≤FEV1 < 80% predicted 
 
           Stage III: severe                      FEV1/FVC < 0.70 
                                                           30% ≤FEV1 < 50% predicted 
 
           Stage IV: Very Severe            FEV1/FVC < 0.70 
                                                           FEV1 < 30% predicted or FEV1 < 50% 
                                                           predicted plus chronic respiratory 
                                                           failure. 
 
 
 
  
SYMPTOMS OF COPD 
The characteristic symptoms of COPD are chronic and progressive 
dyspnea, cough, and sputum production. Chronic cough and sputum 
production may precede the development of airflow limitation by many 
years. Conversely, significant airflow limitation may develop without 
chronic cough and sputum production. 
STAGES OF COPD 
Stage I: Mild COPD - Characterized by mild airflow limitation (FEV1/FVC 
< 0.70; FEV1 ≥80% predicted).Symptoms of chronic cough and sputum 
production maybe present, but not always1. 
Stage II: Moderate COPD - Characterized by worsening airflow limitation 
(FEV1/FVC < 0.70; 50% ≤FEV1 < 80%predicted), with shortness of breath 
typically developing on exertion and cough and sputum production 
sometimes also present1. 
Stage III: Severe COPD - Characterized by further worsening of airflow 
limitation (FEV1/FVC < 0.70; 30% ≤FEV1< 50% predicted), greater 
shortness of breath, reduced exercise capacity, fatigue, and repeated 
exacerbations that almost always have an impact on patients’ quality of life1. 
  
Stage IV: Very Severe COPD - Characterized by severe airflow limitation 
(FEV1/FVC < 0.70; FEV1 < 30% predicted or FEV1 < 50% predicted plus 
the presence of chronic respiratory failure). Respiratory failure is defined as 
arterial partial pressure of oxygen (PaO2) less than 8.0 kPa (60 mm Hg) with 
or without arterial partial pressure of CO2 (PaCO2) greater than 6.7 kPa (50 
mm Hg) while breathing air at sea level. Respiratory failure may also lead to 
effects on the heart such as cor pulmonale (right heart failure). At this stage, 
quality of life is very appreciably impaired and exacerbations may be life 
threatening1. 
EPIDEMIOLOGY  
COPD is under diagnosed and under treated, resulting in 
underestimation of the burden of this disease12. The prevalence of COPD is 
highest in countries where cigarette smoking, for example, is still very 
common13. Prevalence data based on the presence of airflow limitation 
provide an accurate estimate of the burden of clinically significant COPD14. 
Two large epidemiologic studies, in which the diagnosis of COPD 
was established using spirometry, evaluated COPD prevalence in 2005. In a 
nationwide Korean survey involving 9,243 subjects, Kim and colleagues 
reported that the prevalence of COPD, determined by criteria of the GOLD, 
  
was 17.2% among subjects older than 45 years15. Prevalence increased with 
increasing age, especially in males, in those with more than 20 pack-years of 
smoking, and in low-income subjects. Most of the COPD found was mild to 
moderate (FEV1 > 50%), Menezes and colleagues reported wide variability 
in COPD prevalence between five major cities in Latin America16. 
RISK FACTORS FOR COPD 
1)   Genes: polygenic and hereditary deficiency of alpha-I antitrypsin17. 
2)   Exposure to particles 
• Tobacco smoke18, 19. 
• Occupational dusts, organic and inorganic20-23. 
• Indoor air pollution from heating and cooking with biomass in 
poorly vented dwellings24-30. 
• Outdoor air pollution. 
3)   Decreased Lung Growth and Development31. 
4)   Oxidative stress. 
  
5)   Gender: prevalence is more in males compared to females. However 
in developed countries prevalence is almost equal32-33.  
6)   Age: prevalence increases with increase in age. 
7)   Respiratory infections. 
8)   Socioeconomic status: risk of COPD is inversely related to     
socioeconomic status34.  
9)   Nutrition. 
10)  Co morbidities. 
PATHOLOGICAL CHANGES  
Proximal airways - Inflammatory cells: Macrophages and CD8+ T cells. 
Structural changes: Goblet cells, enlarged submucosal glands and squamous 
metaplasia of epithelium35. 
Peripheral airways - Inflammatory cells: Macrophages, T lymphocytes 
(CD8+ > CD4+), B lymphocytes and fibroblasts. 
  
Structural changes: Airway wall thickening, peribronchial fibrosis, luminal 
inflammatory exudates and  airway narrowing36.  
Lung parenchyma - Inflammatory cells: Macrophages, CD8+ T 
lymphocytes. 
Structural changes: Alveolar wall destruction, apoptosis of epithelial and 
endothelial cells, Centrilobular and Panacinar emphysema37. 
Pulmonary vasculature - Inflammatory cells: Macrophages, T lymphocytes  
Structural changes: pulmonary hypertension38. 
PATHOGENESIS 
Amplification of the normal inflammatory response of the respiratory 
tract to chronic irritants appears to be seen in COPD. 
Inflammatory Cells: COPD is characterized by recruitment of neutrophils, 
macrophages, and lymphocytes39 .These cells release inflammatory 
mediators and interact with structural cells in the airways and lung 
parenchyma. 
  
Inflammatory Mediators: Chemotactic factors like leukotriene B4 and 
interleukin-8, Proinflammatory cytokines like TNF-alpha, IL-1beta, and IL-
6, and Growth factor TGF-ß which are released from the inflammatory cells 
are responsible for inflammation40.  
Oxidative Stress:  Oxidative stress may be an important amplifying 
mechanism in COPD41. Oxidants are generated by cigarette smoke and other 
inhaled particulates and released from activated inflammatory cells. 
Oxidative stress has several adverse consequences in the lungs, including 
activation of inflammatory genes, inactivation of antiproteases, stimulation 
of mucus secretion, and stimulation of increased plasma exudation. 
Protease-Antiprotease Imbalance: There is compelling evidence for an 
imbalance in the lungs of COPD patients between proteases and 
antiproteases1.There is increase in proteases such as Neutrophil elastase, 
Cathepsin G, Proteinase 3, Cathepsins B, K, L, S and matrix 
metalloproteinases like MMP-8, MMP-9 and MMP-12.This is associated 
with decrease in antiprotinases like alpha-1 antitrypsin, alpha-1 
antichymotrypsin, Elafin, Cystatins and Tissue inhibitors of MMP 1-4.  
 
  
PATHOPHYSIOLOGY 
1) Airflow Limitation and Air Trapping: The peripheral airway 
obstruction due to inflammation, fibrosis, and luminal exudates leads to 
progressive air trapping during expiration resulting in hyperinflation. 
Hyperinflation increases functional residual capacity which results in 
dyspnea and limitation of exercise capacity. 
2) Gas Exchange Abnormalities:  results in hypoxemia and Hypercapnia. 
3) Mucus Hypersecretion:  is due to mucous metaplasia with increased 
numbers of goblet cells in response to chronic airway irritation resulting in 
chronic productive cough. 
4) Pulmonary Hypertension: pulmonary hypertension may develop late in 
the course of COPD and is due to hypoxic vasoconstriction and structural 
changes in small pulmonary arteries42. 
 
 
 
  
SYSTEMIC FEATURES 
It is increasingly recognized that COPD involves several systemic 
features, particularly in patients with severe disease43, 44. 
Systemic Features of COPD 
• Systemic inflammation 
• Cachexia: loss of fat free mass 
• Skeletal muscle wasting: apoptosis, disuse atrophy 
• Osteoporosis 
• Depression 
• ormochromic normocytic anemia 
• Increased risk of cardiovascular disease: associated with CRP45. 
  
SYSTEMIC INFLAMMATION IN COPD 
Circulating Inflammatory Cells 
Many studies of COPD have reported changes in various 
inflammatory cells, including neutrophils and lymphocytes, in peripheral 
blood. The activation of peripheral blood neutrophils, resulting in 
potentiation of cytotoxic and migratory responses, has also been shown. 
Noguera and colleagues investigated the production of reactive oxygen 
species and the expression of surface adhesion molecules in circulating 
neutrophils of patients with stable COPD46, 47. Compared with control 
subjects, patients with stable disease showed an increased expression of 
CD11b/CD18 in circulating neutrophils with lower expression levels of 
ICAM-1. Increased plasma soluble ICAM-1, a surrogate of its expression on 
the endothelium, was reported by others. In addition, Noguera and 
coworkers showed that blood neutrophils isolated from patients with COPD 
produced more reactive oxygen species under basal conditions as well as 
after stimulation in vitro, as compared to neutrophils from smoking and 
nonsmoking control subjects and this respiratory burst correlated with the 
elevated expression of adhesion molecules47. In another study, Burnett and 
colleagues demonstrated that peripheral neutrophils isolated from patients 
  
with COPD showed enhanced chemotaxis and extracellular proteolysis in 
vitro48, 49. In contrast, Cataldo and coworkers found no differences in the 
secretion of matrix metalloproteinase (MMP)-9 by circulating granulocytes 
comparing patients with COPD and control subjects50. The expression of 
stimulatory Ga, a G protein subunit that is a key signaling protein for cell 
adhesion and activation in circulating neutrophils, has been shown to be 
downregulated irrespective of the clinical condition of the patient. However, 
the pathogenic implications of most of these findings are still unclear, and 
need confirmation in well characterized patient groups. 
Recent findings also indicate abnormal lymphocyte function in 
COPD. Increased activity of cytochrome oxidase was reported in the 
lymphocytes of patients with COPD compared with healthy subjects 51, and 
found to be significantly related to disease severity as reflected by the degree 
of airflow limitation. In a recent study, Hageman and colleagues 52 
investigated activation of nuclear enzyme poly ADP-ribose polymerase-1 
(PARP-1), which forms extensive poly ADP-ribose polymers from its 
substrate NAD +  after activation by reactive oxygen species–induced DNA 
strand breaks. Activation of PARP-1 in peripheral blood lymphocytes of 
patients with COPD was more prevalent than in lymphocytes of healthy, 
age-matched control subjects, supporting a contribution of PARP-1 
  
activation to the pathophysiology of COPD. PARP-1 activation was 
associated with a reduction of the NAD+ status, the consequences of which 
can include impaired production of high-energy phosphates. 
In contrast to numerous studies showing a decreased pulmonary 
CD4+/CD8+ ratio in COPD, this has not to date been studied as extensively 
in the systemic compartment. Several reports suggest that cigarette smoke 
alone may trigger a shift in the numbers of CD4+ and CD8+ lymphocytes, 
which may be reversible after smoking cessation. In this respect De Jong 
and coworkers reported no significant differences between lymphocyte 
subsets in peripheral blood of patients with COPD and healthy smokers53. 
However, these authors also found that, within the group of nonsmokers, the 
percentage of CD8+ cells was significantly higher in subjects with COPD 
compared with control subjects and the CD4:CD8 ratio correlated positively 
with higher FEV1 values. Additional studies are necessary to understand 
better the contribution of circulating lymphocytes to the pathogenesis of 
COPD. 
The propensity of circulating monocytes to release proinflammatory 
molecules as a possible factor in a systemic inflammatory response was 
evaluated recently in stable COPD. Monocytes isolated from patients with 
  
COPD release significantly more MMP-9 but less IL-8 than control 
subjects54. Cell stimulation resulted in a larger enhancement of IL-6 and 
MCP-1 release from COPD monocytes, whereas monocytes from healthy 
individuals released higher levels of ICAM-1. As a consequence of cellular 
inflammatory changes, different authors have reported changes in the 
oxidant/antioxidant balance in the systemic circulation. Markedly reduced 
Trolox-equivalent antioxidant capacity (TEAC) of plasma, as well as 
increased levels of lipid peroxidation products, both indices of overall 
oxidative stress, are seen in healthy smokers and patients with COPD versus 
nonsmoking control subjects55, 56. Hageman and coworkers demonstrated a 
significant reduction of TEAC of deproteinized plasma as well as a 
reduction of plasma uric acid in patients with stable COPD when compared 
with control subjects52. Further evidence of persistent systemic oxidative 
stress in patients with COPD was provided by the finding of higher levels of 
isoprostane F2alpha -II, a stable prostaglandin isomer formed by reactive 
oxygen species-dependent peroxidation of arachidonic acid, in the urine of 
patients with COPD versus smoking control subjects57. Together these 
studies indicate that both smoking and COPD are associated with significant 
systemic oxidative stress. 
  
Inflammatory Mediators in Plasma: During the last decade, several 
studies investigating systemic manifestations of COPD have reported 
enhanced levels of circulating inflammatory mediators, such as acute-phase 
reactants and cytokines. The acute-phase proteins are liver-derived, key 
players in innate immunity and reduction of inflammatory reactions. Schols 
and colleagues demonstrated increased levels of C-reactive protein and 
lipopolysaccharide binding protein in patients with stable COPD58, and 
which was most pronounced in a subset of patients with COPD with an 
increased resting energy expenditure and decreased fat-free mass. The lack 
of a response to some intervention strategies such as nutritional therapy 
seems to be related to the level of this systemic inflammatory response. A 
prospective epidemiological study in a cohort of 8,955 subjects from a 
Danish general adult population study revealed that increased plasma levels 
of fibrinogen, another acute-phase reactant, are associated with reduced lung 
function and increased risk of COPD, independent of smoking status59. The 
rise in the systemic levels of acute-phase proteins suggests that hepatocytes 
are activated to produce these reactants, although increasing evidence 
indicates that other tissue specific cells such as lung epithelial cells are also 
able to produce acute-phase proteins. The formation of acute-phase reactants 
is induced strongly by cytokines such as IL-6 or TNF-alpha .Indeed, 
  
enhanced circulating levels IL-6 and TNF-alpha have been reported in 
COPD52. These increased levels of proinflammatory mediators are not 
counterbalanced by up regulation of anti-inflammatory mediators like 
soluble IL-1RII in patients with stable COPD60. Yasuda and colleagues 
demonstrated that plasma levels of soluble Fas (CD95), an inhibitor of 
apoptosis, were increased significantly in severe COPD when compared to 
healthy control subjects and patients with mild/moderate COPD61. 
Upregulation of apoptotic pathways, TGF-β, TNF-α and Fas in peripheral 
blood in patients with COPD was associated with increased T cell death. 
Future studies are needed to assess whether these systemic changes are 
present continuously as part of the stable state in COPD or reflect day-to-day 
variations in the inflammatory state. 
ORIGIN OF SYSTEMIC INFLAMMATION 
The origin of the systemic inflammation present in patients with 
COPD remains poorly understood, and several (independent) pathways may 
be involved. As smoking causes many important extrapulmonary effects, 
like cardiovascular diseases, tobacco smoke alone may contribute 
significantly to systemic inflammation in COPD. In this respect, both 
systemic oxidative stress and peripheral vascular endothelial dysfunction 
  
were reported in passive smokers and in smokers with only few pack-years. 
A second possible mechanism is the involvement of the local pulmonary 
inflammatory response in systemic inflammation, which was investigated 
recently by Vernooy and coworkers62. Comparison of levels of sTNF-R or 
IL-8 in sputum and plasma did not reveal direct correlations, thereby 
suggesting that the systemic inflammatory response in mild-to-moderate 
COPD is not due to an overflow of Inflammatory mediators from the 
pulmonary compartment but, rather, that the inflammatory processes in the 
local and systemic compartment are regulated differently. Further evidence 
for the hypothesis that the inflammatory processes in the airways and the 
systemic circulation are independent processes comes from recent studies of 
Michel and colleagues63. 
A third pathway involved in the process of systemic inflammation 
could be related to hypoxia, a recurrent problem in COPD. As studies in 
vitro have revealed that hypoxia results in enhanced cytokine production by 
macrophages, the systemic hypoxemia observed in patients with COPD may 
contribute to the activation of the TNF system. Indeed, significant inverse 
correlations between PaO2 and circulating TNF-alpha and sTNF-R levels in 
patients with COPD were reported64. Alveolar macrophages appear to have a 
prominent role in the inflammatory response in hypoxia-induced lung injury 
  
and the related up regulation of inflammatory mediators. Based on the 
observation of decreased antioxidative capacity of skeletal muscles in 
COPD, Rabinovich and coworkers have demonstrated an abnormal cytokine 
response to moderate exercise in patients with COPD. Recently, it was 
reported that local muscle exercise, despite the increased oxidative stress, 
did not result in changes in plasma cytokine levels. Further research is 
needed to clarify the origin and physiological significance of these exercise-
related inflammatory responses in COPD. 
 
 
 
 
 
 
 
  
CARDIOVASCULAR DISEASES AND COPD 
Chronic obstructive pulmonary disease (COPD) is an important risk 
factor for atherosclerosis3-5. Even modest reductions in expiratory flow 
volumes elevate the risk of ischemic heart diseases, strokes, and sudden 
cardiac deaths 2-to 3-fold, independent of other risk factors3-7. Indeed, poor 
lung function has been shown to be a better predictor of all-cause and 
cardiac-specific mortality than established risk factors such as serum 
cholesterol5. Cardiovascular conditions are the leading cause of mortality 
among those with impaired lung function3, 5, 7. The mechanism or 
mechanisms responsible for this association, however, remain largely 
unknown. Of course tobacco smoking is a shared risk factor for both COPD 
and cardiovascular disease. Yet it is possible that others factors may increase 
the Cardiovascular risk of patients with COPD even further. 
Although the pathogenesis of atherothrombosis is complex and 
multifactorial, persistent low-grade systemic inflammation is believed to be 
one of the centerpieces in effecting clot formation8. Compelling 
epidemiological data link systemic inflammation to atherosclerosis, ischemic 
heart disease, strokes, and coronary deaths65,66.These observations have been 
strongly supported by biomedical experiments that show the direct effects of 
  
certain inflammatory markers, such as C-reactive protein (CRP), on the 
pathogenesis of  plaque formation67,68. 
Sin DD et al69 showed that systemic inflammation is present in 
moderate and severe COPD and airflow obstruction is an important risk 
factor for cardiac injury. They also showed that in the presence of elevated 
CRP, the risk increases almost 2-fold, which suggests an important interplay 
of systemic inflammation with airflow obstruction in the development of 
ischemic heart disease. Sin et al showed that in COPD patients, every 10% 
reduction in FEV1 equate to an increase in cardiovascular mortality of 
28%.Huiart et al70 using Saskatchewan Health databases showed that 
Cardiovascular morbidity and mortality rates were higher in the COPD 
cohort than in the general population. More hospitalizations for CVD than 
for COPD itself were reported. Cardiovascular disease and more specifically 
ischemic heart disease were reported as a more frequent cause of death than 
COPD itself. Miller et al and sin et al69 showed that CRP and cardiovascular 
infarction injury score increases as the severity of COPD increases. COPD 
patients have increased arterial stiffness compared to healthy controls as 
measured by applanation tonometry. Endothelial dysfunction and arterial 
stiffness may also contribute to adverse cardiovascular events in COPD. 
  
The epidemiologic evidence linking COPD and cardiovascular 
morbidity and mortality is strong. Even after adjustments for traditional 
cardiovascular risk factors such as serum total cholesterol, hypertension, 
obesity and smoking, patients with COPD have a two- to threefold increase 
in the risk of cardiovascular events including death71. 
But there remain many unanswered questions. First, there is a scarcity 
of studies that evaluated COPD as a potential effect modifier of 
cardiovascular events in individuals with pre-existing heart disease. Second, 
it is not clear whether COPD amplifies the adverse effects of cigarette 
smoking on the cardiovascular system or whether it acts predominantly via 
the smoke–heart disease causal pathway. Third, the mechanisms through 
which COPD contributes to atherosclerosis and, ultimately, cardiovascular 
events are not fully known. Finally, it is not clear whether anti-COPD 
interventions, aside from smoking cessation, can modify cardiovascular risks 
in COPD. 
 
 
 
 
 
 
  
MATERIALS AND METHODS 
SETTINGS  
Institute of internal medicine, 
Madras Medical College and Government general hospital  
Chennai - 600 003. 
ETHICAL APPROVAL 
         Obtained  
STUDY DESIGN 
         To evaluate the presence of systemic inflammation in COPD patients 
and whether both are associated with cardiac injury, a cross sectional study 
design was chosen. 
PERIOD OF STUDY 
          May 2006 TO June 2007 
SAMPLE SIZE 
 Cases: 70, Controls: 30  
 
  
INCLUSION CRITERIA 
            1.  Patients with symptoms suggestive of COPD. 
            2.  Patients with age more than 45 years. 
            3.  Patients not on corticosteroids. 
EXCLUSION CRITERIA 
1. Patients with cor pulmonale 
2. Patients with pulmonary tuberculosis 
3. Patients with diabetes mellitus  
4. Patients known to have systemic hypertension 
5. Patients who are unable to perform spirometry 
6. Critically ill patients 
7. Patients having elevated lipid profile 
8. Patients having angina, cardiac or renal failure 
STUDY POPULATION 
                          Of the 100 patients enrolled for the study who attended out patient    
clinic of  Institute of Internal Medicine, Government General hospital,50 
  
patients were selected as cases and 30 as controls after thorough history 
taking and clinical examination. Other 20 patients were excluded as per 
exclusion criteria. 
              The patients having following criteria [according to GOLD1] were 
defined as having COPD 
1. The presence of cough and sputum production for at least 3 months 
in each of two consecutive years. 
2. Exertional dyspnoea. 
3. Physical examination showing (a) signs of airflow limitation like 
prolonged expiration and expiratory wheeze which is not fully 
reversible. (b) Signs of hyperinflation. 
4. Spirometry showing post-bronchodilator FEV1/FVC ratio < 0.70. 
                   The present analysis was restricted to participants >45 years of 
age who performed spirometry that met acceptability and reliability criteria 
of the American Thoracic Society72. This age cutoff was chosen in order to 
improve the diagnostic accuracy of using airflow obstruction as a marker of 
COPD. 
  
For each enrolled subject, the personal and family medical histories 
were obtained. On the study day, height and weight were measured twice 
during the examination. Weight was measured to the nearest 100 g with bare 
foot. Height was measured to the nearest mm with a stadiometer. Body mass 
index (BMI) was calculated by the formula  
                          BMI = Weight (kg) / Height (m) 2  
Blood pressure was measured was measured with patient in the sitting 
position after a 5 min rest, with mercury sphygmomanometer (cuff size 12.5 
× 40 cm). The systolic BP and diastolic BP were read to the nearest 2 
mmHg. Disappearance of Korotkoff’s sounds (phase 5) was the criterion for 
diastolic BP. Total amount of smoking was determined by calculating Pack-
years of smoking. Presence of co morbidities was determined by 
participants’ responses to the question: “Has the doctor ever told you had 
diabetes (hypertension, tuberculosis, congestive heart failure, etc)?” 
  
SPIROMETRY 
           Spirometry was performed with equipment that met the American 
Thoracic Society performance criteria72. To adjust for height, age, sex, and 
race, published prediction equations for forced expiratory volume in 1 
second (FEV1) and forced vital capacity (FVC) was used73. FEV1–FVC 
ratio of<0.70 was used to define airflow obstruction. Mild, moderate, and 
severe airflow obstruction were defined as FEV1 of <80% of predicted 
(equivalent to Stage 1 of the [GOLD] classification), 50% to 80% of 
predicted (Stage 2a), and <50% of predicted (Stages 2b and 3), respectively1. 
ELECTROCARDIOGRAPHY 
          Standard 12 lead ECG was obtained from each patients. An ECG 
coding scheme was then applied to the data to calculate a Cardiac Infarction 
Injury Score (CIIS) for each participant74. These scores were used to 
estimate the participants’ risk of underlying ischemic heart disease. A CIIS 
score of ≥20 denoted probable infarction, ≥15 possible infarction and ≥10 
borderline abnormality74. 
 
 
  
LABAROTARY MEASUREMENTS 
The hs-CRP level was measured by using latex-enhanced 
nephelometry75. 
Hs-crp values ranges between 0.3 and 8.6 mg/l in healthy men and 
between 0.2 and 9.1mg/l in healthy women who are not taking hormone 
replacement therapy. The recommendation of Centre for Disease Control 
and prevention (CDC) and the American Heart Association (AHA) for 
interpretation of  hs-CRP results was taken into consideration76. It states that 
hs-CRP of 
                                   <1 mg/l          low risk 
                                    1to 3 mg/l     Average risk  
                                    >3 mg/l         High risk. 
Overnight fasting (at least 10 hours) blood specimen were obtained 
for measurement of serum lipids. Concentration of total cholesterol, HDL-
cholesterol, and triglycerides were assessed enzymatically with 
commercially available reagents. Concentration of LDL- cholesterol was 
calculated by use of the Friedewald equation for participants who had 
triglycerides (< 400 mg/dl)    
  
                                  LDL = TC ─ HDL-c ─ TGL/5. 
          Total leukocyte count, differential count, platelets, serum creatinine, 
blood urea, serum electrolytes, and other biochemical evaluation were 
performed according to routine standards, at biochemical lab attached to 
Institute of Biochemistry, Government General Hospital. 
FINANCIAL SUPPORT: nil. 
CONFLICT OF INTEREST: nil. 
 
 
                                     
 
 
 
 
 
  
STATISTICAL ANALYSIS 
Statistical analysis was carried out for 80 participants [50 COPD 
patients, 30 controls] after categorizing each variable. Base line data was 
collected from patients without and with mild, moderate and severe 
obstruction. Age, sex, smoking in pack years, blood pressure, body mass 
index, spirometric results, total leukocyte count, differential count, platelets, 
CRP and CIIS were analyzed.  
The significance of difference in means between two groups were 
analyzed using One way ANOVA F-test and the significance of difference in 
proportions by Chi-square test. Multiple comparisons were done by 
Bonferroni t-test. The correlation between CIIS and severity of COPD was 
done by spearman’s rho methods. 
Statistical significance was taken when p value < 0.05. Statistical 
analysis was carried out using standard formulae. Microsoft excel 2003 and 
SPSS (statistical package for social sciences) version 13 software was used 
for data entry and analysis. 
                                                     
  
                                               
RESULTS 
There were totally 80(68.8% males, 31.3% females) participants in the 
study, out of which 50 (62.5%) had airflow obstruction on their spirometry. 
16 (32%) had mild, 13(26%) had moderate and 21(42%) had severe 
obstruction. 
Table 1:  Age Distribution in years 
 
 
 
N Mean 
Std. 
Deviation 
Oneway 
ANOVA 
F-test 
Normal 30 55.47 5.794 
Mild 16 56.69 6.008 
Moderate 13 59.08 8.361 
Severe 21 56.43 8.675 
Total 80 56.55 7.096 
F=0.78 
P=0.51 
Not 
significant 
   
The average age of participants was 56.55 years. There was no 
statistical significance (p=0.51) between increase in age and severity of 
airflow Obstruction.    
      
  
 
 
 
 
Table 2: Sex distribution 
 
Sex 
Male Female 
 
 
 n % n % 
Chi-square test 
 
Normal 15 50.0% 15 50.0% 
Mild 9 56.3% 7 43.8% 
Moderate 10 76.9% 3 23.1% 
Severe 21 100.0% 0 0.00% 
Total 55 68.8% 25 31.3% 
χ2=16.02 
P=0.001 
significant 
 
Out of 50 participants who had airflow obstruction 80% were males 
and 20% were females. Male sex was significantly associated with airflow 
obstruction (mild, moderate and severe) compared to female sex (p=0.001). 
 
           
 
  
 
 
 
Table 3: Smoking status 
 
 
 Smoker 
 No Yes 
 n % n % 
Chi-square test 
 
Normal 24 80.0% 6 20.0% 
Mild 10 62.5% 6 37.5% 
Moderate 5 38.5% 8 61.5% 
Severe 1 4.8% 20 95.2% 
Total 40 50.0% 40 50.0% 
χ2=29.68 
P=0.001 
significant 
 
All smokers were males in the study. Smoking status was a positive 
risk factor for moderate and severe airflow obstruction (p=0.001). 
                           
  
 
 
Table 4: Smoking in pack years 
 
 
N Mean 
Std. 
Deviation 
Oneway 
ANOVA 
F-test 
Normal 6 21.267 2.0027 
Mild 6 17.083 5.5715 
Moderate 8 37.250 35.8589 
Severe 20 38.777 19.0856 
Total 40 27.591 21.3482 
F=2.91 
P=0.05 
significant 
                                  
 
Severity of airflow obstruction was significantly associated with 
number of years of smoking. Severity increased as the number of pack years 
of smoking increased and it was statistically significant (p=0.05). 
 
                                       
  
 
 
Table 5: Body Mass Index (kg/m2) 
 
 
N Mean 
Std. 
Deviation 
Oneway 
ANOVA
F-test 
Multiple comparison 
By Bonferroni t-test 
Normal 30 24.930 2.0024 
Mild 16 20.299 2.7299 
Moderate 13 21.046 3.7362 
Severe 21 19.749 3.5349 
Total 80 22.013 3.6760 
F=16.56 
P=0.001 
significa
nt 
1 Vs 2,3,4 
   
The average BMI of the participants was 22.013 kg/m2.It was 
inversely correlated with lung function. Compared to the controls, BMI of 
the cases was low and as the severity of airflow increased, BMI reduced, 
which was statistically significant (p=0.002). 
                     
  
 
Table 6: Systolic blood pressure in mm of Hg 
 
 N Mean 
Std. 
Deviation 
Oneway 
ANOVA 
F-test 
Normal 30 125.87 6.410 
Mild 16 128.00 5.750 
Moderate 13 130.15 9.326 
Severe 21 123.90 12.609 
Total 80 126.48 8.912 
F=1.56 
P=0.21 
Not 
significant 
 
 
There was no significant differences in systolic blood pressure 
between the cases and controls (p=0.21). 
                    
  
 
Table 7: Diastolic blood pressure in mm of Hg 
 
 
 
N Mean 
Std. 
Deviation 
Oneway 
ANOVA 
F-test 
Normal 30 76.33 7.576 
Mild 16 77.88 5.439 
Moderate 13 80.77 7.049 
Severe 21 78.29 6.141 
Total 80 77.88 6.790 
F=1.34 
P=0.27 
Not significant 
 
Diastolic blood pressure between cases and controls was also not 
statistically significant (p=0.27). 
 
  
 
Table 8: Leukocytes per mm3 
 
 N Mean 
Std. 
Deviation 
Oneway 
ANOVA
F-test 
Multiple 
comparison 
By Bonferroni t-
test 
Normal 30 6046.67 783.332 
Mild 16 6593.75 711.307 
Moderate 13 7623.08 485.032 
Severe 21 8090.48 814.804 
Total 80 6948.75 1131.818 
F=36.47 
P=0.001 
significa
nt 
1 Vs3,4 
2Vs 3,4 
3 Vs 1,2 
4Vs 1,2 
 
                                                      
Compared to control, cases with moderate and severe airflow 
obstruction were having elevated levels of leukocytes (p=0.001), where as 
significant difference was not found between control and cases with mild 
obstruction. The highest levels were observed in the group with severe 
airflow obstruction. 
                               
  
 
 
                                   Table 9: Neutrophils   per mm3                                               
 
 
N Mean 
Std. 
Deviation 
Oneway 
ANOVA
F-test 
Multiple 
comparison 
By Bonferroni t-
test 
Normal 30 3952.97 539.330 
Mild 16 4295.38 445.713 
Moderate 13 4924.92 443.059 
Severe 21 5414.81 688.065 
Total 80 4563.13 815.125 
F=31.88 
P=0.001 
significa
nt 
1 Vs3,4 
2Vs 3,4 
3 Vs 1,2 
4Vs 1,2 
 
 
The circulating levels of neutrophils were higher in participants with 
than in those without airflow obstruction (p=0.001). The highest levels were 
observed in the group with severe airflow obstruction. The increase in 
leukocyte count in this group was driven largely by the neutrophilic 
subpopulation of cells. 
                                  
 
 
  
 
 
Table 10: Lymphocytes per mm3 
 
 
N Mean 
Std. 
Deviation 
Oneway 
ANOVA
F-test 
Multiple 
comparison 
By Bonferroni t-
test 
Normal 30 1842.10 319.097 
Mild 16 1904.69 470.044 
Moderate 13 2388.23 239.409 
Severe 21 2465.86 335.273 
Total 80 2107.10 445.732 
F=17.87 
P=0.001 
significa
nt 
1 Vs3,4 
2Vs 3,4 
3 Vs 1,2 
4Vs 1,2 
 
  
The circulating levels of lymphocytes was also higher in cases with 
moderate and severe airflow obstruction compared to controls and cases 
with mild obstruction (p=0.001).There was no statistically significant 
differences between the latter two groups. 
 
                                     
                                     
 
  
 
                                 
 
Table 11: Platelets per mm3 
                                          
 
N Mean 
Std. 
Deviation 
Oneway 
ANOVA
F-test 
Multiple 
comparison 
By Bonferroni t-
test 
Normal 30 2.3143 .19833 
Mild 16 2.2813 .28159 
Moderate 13 2.5662 .11608 
Severe 21 2.8643 .22087 
Total 80 2.4930 .32035 
F=33.89 
P=0.001 
significa
nt 
1 Vs3,4 
2Vs 3,4 
3 Vs 1,2,4 
4Vs 1,2,3 
 
 
Similarly the circulating levels of platelets was also higher in cases 
with moderate and severe airflow obstruction compared to controls and 
cases with mild obstruction (p=0.001).There was no statistical differences 
between the latter two groups. Highest levels were noted in severe 
obstruction group.  
 
                                  
  
                                 
Table 12: Hs-CRP in mg/l 
 
 
N Mean 
Std. 
Deviation 
Oneway 
ANOVA
F-test 
Multiple 
comparison 
By Bonferroni t-
test 
Normal 30 3.453 1.7965 
Mild 16 7.400 1.3049 
Moderate 13 8.631 .9050 
Severe 21 12.067 3.4706 
Total 80 7.345 4.0783 
F=64.66 
P=0.001 
significa
nt 
1 Vs,3,4 
2Vs 1,4 
3 Vs 1,4 
4Vs 1,2,3 
 
  
The levels of hs-CRP was significantly elevated in cases with 
moderate and severe airflow obstruction compared to control and cases with 
mild obstruction (p=0.001).Among cases significant differences were noted 
between mild and severe and also between moderate and severe obstruction 
groups. Not much difference was noted between mild and moderate 
obstruction groups. 
   
 
 
  
Table 13 : CARDIOVASCULAR INFARCTION INJURY SCORE 
                                                     (CIIS) 
 
N Mean 
Std. 
Deviation 
Oneway 
ANOVA
F-test 
Multiple 
comparison 
By Bonferroni t-
test 
Normal 30 5.30 1.622 
Mild 16 7.00 2.658 
Moderate 13 10.15 2.075 
Severe 21 13.57 3.385 
Total 80 8.60 4.181 
F=50.21 
P=0.03 
significa
nt 
1 Vs 3,4 
2 Vs 3,4 
3 Vs 1,2 
4 Vs 1,2 
 
There were important differences in ECG findings among the four 
lung function groups. Compared with the control group, moderate, and 
severe airflow obstruction were associated with an increase in CIIS of 
4.85+_0.453, and 8.27+_1.76 U, respectively which was statistically 
significant (p=0.03). Even though group with mild obstruction had elevated 
CIIS compared to control, it was not statistically significant.   
 
 
 
  
We assessed the strength of correlation of the CIIS with BMI and 
inflammatory markers. We found that CIIS was positively correlated with 
leukocytes, platelets and CRP, and negatively correlated with BMI. 
 
Table 14:  Correlations 
 
 
SBP 
mm 
hg 
DBP 
mm hg 
BMI 
Kg/m2 
LEUKO 
CYTES 
per mm3 
LYMPHO 
CYTES 
per mm3 
NEUTR 
OPHILS 
per mm3 
PLATELETS 
per mm3 
CRP 
mg/l 
CIIS -.179 .105 -.481(**) .669(**) .448(**) .664(**) .548(**) .675(**)
 .112 .353 .000 .000 .000 .000 .000 .000 
 80 80 80 80 80 80 80 80 
 
0-0.2        poor correlation.   0.2-0.4   fair. 
0.4-0.6     moderate.    0.6-0.8    substantial. 
0.8-1.0     good. 
 
 
 
 
                                                       
  
     
Fig 1: Age distribution 
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Fig 2: Sex distribution 
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Fig 3: Smoking status 
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                        Fig 4: Blood pressure distribution (mm hg) 
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Fig 5: Leukocytes distribution (cu mm) 
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Fig 6: Neutrophils distribution (cu mm) 
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Fig 7: Lymphocytes distribution (cu mm) 
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                         Fig 8: Platelets distribution (lakhs/cu mm) 
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Fig 9: CRP distribution (mg/l) 
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Fig 10: CIIS distribution 
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DISCUSSION 
Many several relevant observations that may have important 
implications for future COPD management and research were made in this 
study. First, although previous studies have shown that severe COPD 
patients have elevated circulating levels of tumor necrosis factor, endothelin-
1, interleukin-6, and CRP compared with healthy controls, these studies 
were limited by restriction of study subjects largely to those with severe 
COPD (FEV1 >50% of predicted)58,64,77,78. Our present study extends these 
findings by demonstrating the presence of systemic inflammation even in 
moderate (FEV1 50% to 80%)  COPD. These data may explain why even 
relatively small reductions in FEV1 can increase the risk of cardiovascular 
morbidity and mortality 2- to 3-fold in the general community3-7.  
Second, although prior studies have shown systemic inflammation in 
severe COPD, 58,64,77,78 only few studies have established a link between 
systemic inflammation in COPD and cardiac injury. Our findings indicate 
that airflow obstruction is an important risk factor for cardiac injury. Even 
moderate obstruction is associated with elevated CIIS compared to healthy 
controls.  In the presence of elevated CRP, this risk increases, which 
  
suggests an important interplay of systemic inflammation with airflow 
obstruction in the development of ischemic heart disease. 
Our study demonstrated that smoking was significantly associated 
with severity of airflow obstruction rather than the age. This shows that it is 
the duration of the smoking which is more important than age in determining 
the severity of COPD and its complications. 
Our observations are similar to those of Sin et al69, who showed the 
association of systemic inflammation and increased cardiovascular injury in 
COPD patients. They used the data from the third National health and 
nutrition examination survey (NHANES III).Their analysis was restricted to 
participants >50 years of age unlike our study where the lower limit of age 
was 45 years. 
In our study females formed only 20% of those with airflow 
obstruction, whereas in the study done by Sin et al69, percentage of females 
with airflow obstruction was almost equal to that of males (46.4 %). This 
could be explained by increased prevalence of smoking in western females. 
But male sex was a positive risk factor for severe airflow obstruction in their 
study which was similar to our study. 
  
 
Our study also showed that smokers had an increased severity of 
obstruction, systemic inflammation and cardiovascular injury compared to 
nonsmokers which was similar to Sin et al69 study. But even among non 
smokers low grade systemic inflammation was seen in those with chronic 
airflow limitation. 
Study done by us showed that BMI is inversely correlated with 
severity of airflow obstruction similar to that of Sin et al69.This is due to 
increasing levels of inflammatory cytokines as the severity of airflow 
obstruction increases. 
Our study did not show significant differences in systolic blood 
pressure among the four groups. But Study done by Sin et al69 showed that 
systolic blood pressure was elevated in those with severe airflow obstruction 
compared with controls. But no differences were noted between the other 
lung function groups. Significant differences were not observed in diastolic 
blood pressure in both the studies. 
Our study showed that moderate and severe airflow obstruction was 
associated with increased levels of circulating leukocyte, platelets, and CRP. 
  
This was similar to the study done by Sin et al69   who showed that 
participants with severe and moderate airflow obstruction had increased 
levels of these inflammatory markers. Mild airflow obstruction was not 
associated with elevations in any of these measurements in both the studies. 
Compared with the controls both studies demonstrated that moderate 
and severe airflow obstructions were associated with an increase in CIIS. 
Our observations are also similar to those of Cirillo et al79, who 
showed an inverse association between FEV1 and serum CRP. Unlike our 
study, however, they included all adult NHANES participants (increasing 
the risk of confounding by age). They also did not use a prediction equation 
for FEV1 to adjust for differences in age, sex, height, and race of study 
participants, which could have led to residual confounding by these 
variables. More importantly, the study by Cirillo et al79 did not evaluate the 
role of airflow obstruction (or its severity) on systemic inflammation. Our 
study has extended the findings of Cirillo et al79 and has shown that 
moderate to severe (but not mild) COPD is strongly associated with systemic 
low-grade inflammation and ECG evidence of ischemic heart disease. 
 
  
Similar study was conducted by Miller et al and they also showed that 
reduced FEV1 seen in COPD  was associated with increased cardiovascular 
risk (FRS, r=0.34, p<0.0001), and cardiac injury (CIIS, r=-0.34, 
p<0.0001).Cardiac injury scores were higher in patients with COPD than in 
healthy controls (8, 8±0.9vs.4.0±1.8units,p<0.04) and were greatest in 
patients with the most severe airflow obstruction (9.8±1.3units). CRP 
concentration increased with progressive airflow obstruction (2.0±0.4, 
4.7±1.2, 5.2±0.7, 9.5±2.6 mg/L, FEV1 quartiles). 
CRP was concentrated in the present study because it has been shown 
to upregulate the production of proinflammatory cytokines and tissue factors 
by monocytes, increase the uptake of LDL by macrophages, and directly 
induce expression of adhesion molecules by human endothelial cells. 
Additionally, CRP may deposit directly into the arterial wall during 
atherogenesis, interacting with other inflammatory mediators to create foam 
cells, which serve as building blocks of atherosclerotic plaques80. 
Leucocytosis and thrombocytosis also promote plaque formation but likely 
through different pathways81. Because neutrophilic inflammation may 
destabilize atherosclerotic plaques, leading to their rupture, our finding of 
increased circulating neutrophils among participants with severe airflow 
obstruction also may be relevant82. 
                                       
  
 
STUDY LIMITATIONS 
1. The study is a hospital based study and may not be representative of 
general population. 
2. As a cross-sectional study, the present analysis is limited in its  
ability to elucidate causal relationships between risk factors and     
outcome. 
3. It is not known whether the reduction of proinflammatory markers 
would improve prognosis in COPD.  
4. There may be alternate mechanistic pathways that may be responsible 
for cardiovascular complications in COPD.  
5. Medication effects on circulating CRP and other inflammatory     
markers should also be considered. 
 
 
  
                                      
CONCLUSIONS 
1. The prevalence of COPD is high in males compared to females. 
2. BMI is inversely correlated with the severity of the COPD. 
3. COPD is associated with increased circulating levels of CRP and 
other inflammatory markers. 
4. Intensity of the systemic inflammation increases with increase in the 
severity of airflow obstruction. 
5. Airflow obstruction is associated with cardiac injury in patients with 
COPD. 
 
 
 
 
 
  
 
SCOPE FOR FUTURE STUDIES 
This study conducted in our Indian population has significant 
observation and potential implications. Our study concluded that COPD is 
associated with systemic inflammation and cardiovascular injury. Future 
studies should determine the absolute risk for developing coronary heart 
disease in patients with COPD. Future studies are also needed to determine 
if certain therapies that reduce the burden of systemic inflammation can lead 
to improved cardiovascular outcomes in COPD. 
It is also necessary to determine what role (if any) the autonomic 
nervous system plays in the pathogenesis of adverse cardiovascular events in 
COPD. 
Data from the present study confer a plausible mechanism to explain 
the strong relationship between COPD and cardiovascular diseases. More 
importantly, they extend the current concept of COPD as a systemic 
inflammatory disorder (and not just an inflammatory disorder of the 
pulmonary system) and provide potential new therapeutic targets to reduce 
cardiovascular complication rates in COPD. 
  
                                                                               
PROFORMA 
 
Name:  
Age:  
Sex: 
Occupation: 
OP No: 
Address: 
Married Y/N: 
Smoker Y/N: 
History if smoking in Pack Years: 
Symptoms:        h/o daily cough and sputum production 
                          h/o breathlessness  
Co morbidities: h/o Diabetes mellitus 
                          h/o hypertension 
                          h/o congestive heart failure 
                          h/o tuberculosis 
Drugs on use:   bronchodilators 
                          Inhaled or oral steroids. 
                          Lipid lowering drugs 
  
                          NSAID 
                          Estrogen or progesterone products 
                          Cardiac glycoside use 
Family H/o DM/HT/ CAD/ CVA 
EXAMINATION 
   Height           weight        BMI         
   Pulse             peripheral pulses       temperature   
   BP (upper limb) 
   CVS              RS            Abd            CNS 
INVESTIGATIONS 
Spirometry: mild                       moderate                  severe obstruction 
Serum inflammatory mediators: leukocytes                       lymphocytes 
                                                  Neutrophils                      platelets 
                                                  Hs-CRP 
Blood glucose- Fasting                           postprandial 
Lipid profile:   TC                 TGL               HDL             LDL    
Sputum for AFB: 
ECG:     sinus rhythm                               probable prior MI 
              CIIS                                            LVH   
              Right axis deviation                    RVH 
  
Simplified Cardiac Infarction Injury Score (CIIS) 
Classifier for Practical Visual Coding of Electrocardiograms 
 
 
Component           Lead                       Feature                        Threshold                      score 
 
   1                           aVL                Q duration in seconds               Q absent                              5 
                                                           (measured to near-                   0.010                                1 
                                                               est threshold)                       0.020                                 3 
                                                                                                            0.030                                9 
                                                                                                            0.040                              10 
                                                                                                            0.050                              12 
 
   2                          aVL                   T amplitude in mm If               ≤ 0.5 or                              3 
                                                            T negative add 2                       ≥ 3 
                                                             points for each mm                    2 
 
   3                         -aVR                  R amplitude in mm =                    -1                                 -R 
                                                            R (subtract 1 point   
                                                            for each mm) 
 
   4                         -aVR                  T amplitude (positive                     0                                   6 
                                                            phase) in mm. Sub-                     1                                   3 
                                                            tract 2 additional                         2                                   0 
                                                            points for each mm                     3                                  -2 
                                                            exceeding 4                                 4                                  -5 
 
   5                         II, aVF                Largest Q:R ampli-                   ≥ 1/20                              12 
                                                            tude ratio 
   
   6                        III, -aVL              Largest Q duration in               ≥ 0.040                               5 
                                                            Seconds 
 
   7                           III                     T amplitude (negative                  > 1                                  5 
                                                             phase) in mm 
 
   8                           V1                    T amplitude (positive                    >2                                  5 
                                                             phase) in mm 
 
   9                           V2                    R amplitude in mm                     < 3 or                               5 
                                                                                                              ≥ 14 
 
  10                          V2                    T amplitude (negative                 ≥ 1/4                                5 
                                                            phase) in mm 
 
  11                          V3                    Q:R amplitude ratio                    > 1/20                              9 
   
  12                          V5                    S amplitude in mm                       < 2                                 5 
CIIS severity levels: level A, CIIS 20, probable injury; 
level B, CIIS 15, possible injury; level C, CIIS 10, borderline abnormality. 
  
 
 
SL SEX AGE 
SMO- 
KER 
SMOK- 
ING BP 
 
BP BMI  SPIROMETRY 
LEUKO- 
CYTES 
LYMPH- 
OCYTES 
NEUTR- 
OPHILS PLATELETS 
HS- 
CRP CIIS 
   YRS  
PACK 
YRS MM HG MM HG KG/M2 MILD OBS MOD OBS 
SEVERE 
OBS CU MM CU MM CU MM LKS/CUMM MG/L  
      SYSTOLIC DIASTOLIC  FEV1>80% 
FEV1 
50-80% FEV1<50%       
1 M 58 - - 140 80 27.3   40 8900 2581 6141 2.95 10.8 11 
2 M 50 + 12.5 124 80 18.65 84   7300 2190 4600 2.5 7.2 4 
3 M 48 + 25 130 80 13.52   41 10800 2700 7776 3.1 10.6 14 
4 M 65 + 120 120 80 18.75  58  7800 2106 5382 2.56 8.2 15 
5 M 73 + 50 134 70 16.66   45 8400 2436 5796 2.6 11 10 
6 M 52 + 10 130 70 16.65 90   7100 2556 4260 2.3 7 7 
7 M 50 + 7.29 110 80 16   32 7900 2370 5372 2.8 24 13 
8 M 51 + 12.5 110 80 16.02   30 8100 2349 5670 2.8 12 21 
9 M 60 + 40 134 80 23.85   33 7600 2280 5168 2.95 10.2 17 
10 M 55 + 3.75 100 70 20.23   32 8800 2816 5808 2.65 10 17 
11 M 47 + 15 110 70 19.14   30 7900 2133 5451 3.1 16 22 
12 M 58 + 30 140 70 22.2  65  7400 2220 5180 2.5 8.2 11 
13 M 53 + 30 100 70 20   40 7800 2886 4680 3.15 10.4 12 
14 M 45 + 12.5 110 70 16.4  70  8200 2624 4510 2.65 7.6 9 
15 M 53 + 25 130 80 17.1   42 8000 2400 5520 2.9 10.6 14 
16 M 49 + 25 134 84 21.48   37 7800 2184 5460 3 9.8 11 
17 M 81 + 90 130 80 22.89   33 8600 3440 5160 2.2 10.4 16 
18 M 65 - - 124 80 20.34 83   7600 584 4560 1.45 6.4 14 
19 M 48 - - 134 80 21.4 86   5600 2016 3360 1.95 7.6 10 
20 M 67 + 8 136 80 23.87  54  8000 2720 5120 2.6 7.6 11 
21 M 68 + 40 140 90 27.73  70  7600 2584 4864 2.4 8 6 
22 M 57 - - 130 80 22.66 88   5600 1400 3920 2 7.3 3 
23 M 55 + 25 130 90 18.96   32 7400 2220 4810 2.6 10.4 11 
24 M 57 + 12.5 140 90 18.96  58  6600 2376 3960 2.65 8.2 12 
25 M 57 + 13.33 124 80 14.45   34 7800 2340 5304 2.9 11 12 
26 M 48 + 25 120 90 24.09   40 7600 2584 4940 2.8 12.2 11 
27 M 65 - - 130 70 16.45  74  8000 2800 4800 2.5 8.2 9 
28 M 65 + 40 140 80 18.46   30 6500 1820 4485 3 11 14 
             
              MASTER CHART 
 
       COPD GROUP (CASES) 
  
 
 
 
 
 
 
 
 
29 M 47 + 27 106 70 18.36   33 8600 2752 5590 3 11.2 13 
30 M 63 + 25 130 80 22.59   45 7600 2508 4560 2.75 10 10 
31 M 60 + 16.66 130 80 22.83   32 8000 2400 5440 2.9 9.6 14 
32 M 54 + 25 136 70 19.65 90   7000 2170 4690 2.3 4.2 6 
33 M 59 + 20 124 80 21.25 85   6500 1820 4550 2.4 7 7 
34 M 50 - - 130 80 20.5  56  7200 2376 4680 2.5 8 10 
35 M 64 + 40 130 84 18.6  54  6900 2070 4485 2.4 9 9 
36 M 52 + 35 120 84 18.4  54  8000 2400 5200 2.6 10 10 
37 M 50 + 20 120 70 21.7 83   5700 1596 3990 2.2 8.2 6 
38 M 58 + 50 130 80 18.2   36 8000 2400 5120 2.9 18.2 12 
39 M 70 + 15 124 80 19.8 81   6600 1914 4356 2.4 7.2 8 
40 M 54 + 30 130 70 22.6   42 7800 2184 5460 3.1 14 10 
41 F 53 - - 118 70 17.7 85   5500 1650 3575 2.5 8.6 7 
42 F 58 - - 134 76 28 84   7000 1960 4760 2.4 7.9 5 
43 F 60 - - 136 80 22 83   6900 2070 4485 2.5 10 8 
44 F 50 - - 124 80 20  60  7500 2400 4950 2.8 9.8 10 
45 F 58 - - 130 80 18.66 90   7100 2343 4544 2.5 8.4 4 
46 F 55 - - 136 86 25.5  65  8000 2080 5600 2.5 9.2 9 
47 F 56 - - 126 80 16.65 92   5800 1740 3770 2.2 8 6 
48 F 64 - - 134 90 20 83   7000 2450 4410 2.4 5.6 8 
49 F 53 - - 124 80 19.68 82   7200 2016 4896 2.5 7.8 9 
50 F 72 - - 136 86 26.24  62  7900 2291 5293 2.7 10.2 11 
  
CONTROLS 
  
SL SEX AGE SMOKER 
SMOK- 
ING BP BP BMI SPIROMETRTY LEUKOCYTES LYMPHOCYTES NEUTROPHILS PLATELETS 
HS -
CRP CIIS 
  YRS  PACK YRS MM/HG MM/HG KG/M2  CUMM CUMM CUMM LKS/CUMM MG/L  
     SYSTOLIC DIASTOLIC         
1 M 52   124 70 26.4 N 5600 2128 3360 2.4 3 4 
2 M 55   134 60 25.2 N 6000 2100 3720 2.1 2.6 4 
3 F 50   114 74 22.6 N 5800 1740 3770 2.6 2 6 
4 M 56   134 84 27 N 7000 2660 4060 2.2 6 5 
5 M 58   120 70 26.4 N 6400 1792 4352 2.5 7.2 3 
6 M 48   114 80 24.6 N 5100 1632 3264 2.1 4 5 
7 F 53   130 80 22.3 N 6000 1680 4200 2.3 5.4 4 
8 F 60   124 84 27.4 N 5700 1995 3591 2.15 2.4 6 
9 F 58   136 90 24.5 N 6200 1860 4340 2.6 1.5 8 
10 M 64 + 25 130 80 23.5 N 5900 1770 3835 2.18 3.4 4 
11 M 50 + 20 124 76 26.4 N 5400 1620 3564 2.5 1.2 5 
12 F 52   130 74 28.2 N 5600 1568 3808 2.4 6 7 
13 F 56   124 80 24.6 N 7200 2304 4536 2.6 3 3 
14 M 55 + 20 132 84 26.8 N 5800 1508 4060 1.9 2.4 4 
15 F 50   114 60 23.4 N 6000 1800 3900 2.2 1 5 
16 F 48   124 80 26.6 N 6100 1525 4270 2.4 2.8 6 
17 F 54   130 70 25.5 N 5500 1650 3575 2.3 3.2 3 
18 M 74   134 86 22.4 N 5800 1972 3480 2.6 8 4 
19 F 62   124 60 24.2 N 5200 1352 3536 2.2 2.3 7 
20 F 56   120 80 22.6 N 4800 1392 3168 2.1 1.6 5 
21 M 54 + 21.6 134 80 26.3 N 8600 2580 5676 2.3 6.4 7 
22 F 53   124 70 26.5 N 5900 1888 3599 2.5 2.3 4 
23 F 50   114 80 25.4 N 6000 1800 3900 2.3 4.2 5 
24 M 56 + 21.4 124 68 18.6 N 8000 2240 5360 2.1 3.6 8 
  
 
 
25 F 66   130 80 24.8 N 6300 2079 3969 2.6 4.5 8 
26 F 54   124 80 23.2 N 6100 1708 4209 2 2 5 
27 M 63 + 19.6 130 80 26.8 N 6100 1952 3965 2.2 3 6 
28 M 54   124 76 24.5 N 5500 1430 3850 2.4 2 4 
29 M 50   130 80 26 N 5800 1798 3712 2.2 3.4 9 
30 M 53   126 74 25.2 N 6000 1740 3960 2.5 3.2 5 
 
  
                                                                               
 
ABBREVIATIONS 
 
1. COPD:  Chronic obstructive pulmonary disease. 
2. GOLD:  Global initiative for chronic obstructive lung disease. 
3. FEV1:    Forced expiratory volume in 1 second. 
4. FVC :     Forced vital capacity. 
5. IL :         Interleukins. 
6. TNF :     Tumor necrosis factor. 
7. TGF :     Tumor growth factor. 
8. MMP :   Matrix metalloproteinases. 
9. TEAC :  Trolox-equivalent antioxidant capacity. 
10.  CRP :    C-Reactive protein. 
11.  BMI :    Body Mass Index. 
12.  CIIS :    Cardiovascular Infarction Injury Score. 
13.  Hs-CRP:  High sensitive C-Reactive protein. 
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